GLP-1
glucagon-like peptide-1 (agonists) — The drug class behind Ozempic and Wegovy — obesity and diabetes treatments reshaping pharma pipelines and food-industry forecasts.
Coverage of GLP-1 is holding steady : 3 signals on the latest tracked day, level with its three-week baseline of 3, across 3 domains (down from 4 a week ago). That makes it the #255 most-covered of the 349 concerns we track.
What’s changed
5 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more · STAT News — All Content · 2026-08-27
- GLP-1 medications beyond weight loss: how far could their benefits extend? · Peter Attia - The Drive · 2026-08-27
- How cost and perception could reshape the GLP-1 market · Reddit r/biotech · 2026-08-22
- FDA/Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway - 09/23/2026 · FDA Drug News · 2026-07-24
- [APPROVAL] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · FDA Drug News · 2026-05-27
- [APPROVAL] FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs · FDA Press Releases · 2026-04-06
What the reporting says
Across 54 tracked stories from 27 outlets, reporting on GLP-1 most often describes regulatory approvals (8), public statements (2), meetings or visits (2), elections (1), acquisition (1), launches or releases (1).
It shows up alongside FDA (16), Novo Nordisk (9).
Two steps out: AI (through FDA, 16 shared stories on the weaker link); Cder (through FDA, 16 shared stories on the weaker link); Clinical Trials (through FDA, 16 shared stories on the weaker link); Colorectal Cancer (through FDA, 16 shared stories on the weaker link).
Tracked since Apr 6, with coverage on 21 separate days — concentrated in Auto and Pharma Regulatory.